This company has been marked as potentially delisted and may not be actively trading. Cardiff Oncology (TROV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock TROV vs. IKT, PLX, IZTC, CRTX, ZIVO, CVM, JATT, CLDI, FNCH, and ALVRShould you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Invizyne Technologies (IZTC), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), CEL-SCI (CVM), JATT Acquisition (JATT), Calidi Biotherapeutics (CLDI), Finch Therapeutics Group (FNCH), and AlloVir (ALVR). These companies are all part of the "medical" sector. Cardiff Oncology vs. Its Competitors Inhibikase Therapeutics Protalix BioTherapeutics Invizyne Technologies Cortexyme ZIVO Bioscience CEL-SCI JATT Acquisition Calidi Biotherapeutics Finch Therapeutics Group AlloVir Cardiff Oncology (NASDAQ:TROV) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership. Do insiders & institutionals have more ownership in TROV or IKT? 10.0% of Cardiff Oncology shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 0.6% of Cardiff Oncology shares are held by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, TROV or IKT? Cardiff Oncology has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Does the media prefer TROV or IKT? In the previous week, Cardiff Oncology and Cardiff Oncology both had 1 articles in the media. Cardiff Oncology's average media sentiment score of 0.00 equaled Inhibikase Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TROV or IKT more profitable? Inhibikase Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -3,688.31%. Cardiff Oncology's return on equity of -202.00% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cardiff Oncology-3,688.31% -202.00% -122.92% Inhibikase Therapeutics N/A -350.63%-201.82% Which has better earnings and valuation, TROV or IKT? Cardiff Oncology has higher revenue and earnings than Inhibikase Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiff Oncology$250K116.28-$16.41M-$2.80-0.94Inhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.57 Do analysts recommend TROV or IKT? Inhibikase Therapeutics has a consensus target price of $6.50, indicating a potential upside of 327.63%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryInhibikase Therapeutics beats Cardiff Oncology on 7 of the 13 factors compared between the two stocks. Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TROV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TROV vs. The Competition Export to ExcelMetricCardiff OncologyBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.07M$267.91M$5.49B$9.54BDividend YieldN/AN/A4.73%4.09%P/E Ratio-0.87N/A28.8623.83Price / Sales116.28327.48371.4866.02Price / CashN/A22.4435.4557.96Price / Book2.8110.418.275.54Net Income-$16.41M-$106.40M$3.25B$259.28M Cardiff Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TROVCardiff OncologyN/A$2.64+11.4%N/A+2.6%$29.07M$250K-0.87N/AGap UpHigh Trading VolumeIKTInhibikase Therapeutics1.6794 of 5 stars$1.73-2.5%$6.50+276.8%+10.9%$128.24MN/A-0.656News CoveragePLXProtalix BioTherapeutics2.2289 of 5 stars$1.51+0.3%$15.00+896.7%+36.2%$119.81M$59.76M-11.58200News CoverageIZTCInvizyne TechnologiesN/A$9.98+0.3%N/AN/A$62.40MN/A0.0029Positive NewsGap UpCRTXCortexymeN/A$1.85-0.5%N/A+127.2%$55.78MN/A-0.6255News CoverageZIVOZIVO BioscienceN/A$10.70-3.2%N/A+18.7%$40.84M$15.85K-2.1910CVMCEL-SCI1.1236 of 5 stars$7.57-12.1%N/A-72.6%$40.29MN/A-15.7743Positive NewsShort Interest ↑JATTJATT AcquisitionN/A$1.64-2.4%N/A-62.8%$28.29MN/A0.003Gap DownHigh Trading VolumeCLDICalidi Biotherapeutics0.3051 of 5 stars$0.70+27.7%N/A-64.7%$25.61MN/A0.0038Short Interest ↑Gap DownHigh Trading VolumeFNCHFinch Therapeutics GroupN/A$12.50-0.4%N/A+556.3%$20.08MN/A-1.42190Gap DownALVRAlloVirN/A$2.93+6.0%N/A-85.4%$14.75MN/A-0.14110Upcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies IKT Competitors PLX Competitors IZTC Competitors CRTX Competitors ZIVO Competitors CVM Competitors JATT Competitors CLDI Competitors FNCH Competitors ALVR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TROV) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
